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Background: The NOURISHED study: Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders.
Eating Disorders (ED) and Borderline Personality Disorder (BPD) are both difficult to treat and the combination
presents particular challenges. Both are associated with vulnerability to loss of mentalization (awareness of one’s
own and others’ emotional state). In BPD, Mentalization Based therapy (MBT) has been found effective in reducing
symptoms. In this trial we investigate the effectiveness and cost-effectiveness of MBT adapted for Eating disorders
(Mentalization Based Therapy for Eating Disorders (MBT-ED)) compared to a standard comparison treatment, Specialist
Supportive Clinical Management (SSCM-ED) in patients with a combination of an Eating Disorder and either a diagnosis
of BPD or a history of self-harm and impulsivity in the previous 12 months.
Methods/Design: We will complete a multi-site single-blind randomized controlled trial (RCT) of MBT-ED vs
SSCM-ED. Participants will be recruited from three Eating Disorder Services and two Borderline Personality
Disorder Services in London. Participants allocated to MBT-ED will receive one year of weekly group and individual
therapy and participants allocated to SSCM-ED will receive 20 sessions of individual therapy over 1 year. In addition,
participants in both groups will have access to up to 5 hours of dietetic advice. The primary outcome measure is the
global score on the Eating Disorders Examination. Secondary outcome measures include total score on the Zanarini
BPD scale, the Object Relations Inventory, the Depression Anxiety Stress Scales, quality of life and cost-
effectiveness. Measures are taken at recruitment and at 6 month intervals up to 18 months.
Discussion: This is the first Randomised Controlled Trial of MBT-ED in patients with eating disorders and symptoms of
BPD and will provide evidence to inform therapy decisions in this group of patients. During MBT-ED mentalization is
encouraged, while in SSCM-ED it is not overtly addressed. This study will help elucidate mechanisms of change in the
two therapies and analysis of therapy and interview transcripts will provide qualitative information about the conduct
of therapy and changes in mentalization and object relations.
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Patients with eating disorders (ED) combined with symp-
toms of borderline personality disorder (BPD) present par-
ticular therapeutic challenges. Symptoms include weight
loss, bulimia, self harm, emotional lability and impulsive
behaviours. During treatment, while some symptoms may
improve, others can worsen. Therefore treatment needs to
address both the eating and personality disorders, and indi-
viduals with both conditions are more likely than those
with eating disorders alone to have a complicated course
with atypical disorders and migration from one disorder
to another [1]. Borderline Personality Disorder has been
shown to respond to Mentalization Based Therapy (MBT)
[2] which targets vulnerability to loss of self-reflectiveness
(mentalizing) which is thought to occur in both BPD
[3,4] and Eating Disorders [5,6]. This project will test
whether MBT is an effective treatment for this troubled
group of patients.
Eating disorders are among the most common causes
of ill health in young people, affecting some 3-4% of
women and 0.3% of men [7,8]. The morbidity associated
with eating disorders is of several types. Low weight,
electrolyte imbalance and nutrient deficiency leads to
serious physical problems which can be fatal if extreme.
Other problems include depression and anxiety [9], so-
cial isolation, family, relationship and occupational diffi-
culties and a substantially reduced quality of life [10].
BPD has a prevalence of 0.7% but a roughly equal sex
distribution [11,12]. It has a broad impact on psycho-
logical, family and social functioning [13]. Symptoms in-
clude mood fluctuations, including depression, outbursts
of anger, deliberate self harm, suicidal behaviour and dis-
turbed relationships.
The two sets of conditions occur together more com-
monly than would be expected. The combination of
Eating and Borderline Personality Disorder symptoms
was noted by Lacey [14] who found that 80% of a series
of patients with bulimia nervosa engaged in at least
three self damaging behaviours and coined the term
“Multi-impulsive bulimia”. The proposed trial will study
this group, although the criteria and the name given,
(ED with symptoms of BPD), differ. Lacey [14] and
Zeeck et al [15] pointed out their very severe morbidity
and the difficulties in treatment they present. The direct
and indirect costs of these problems have not been
reported, although the costs of ED [16-18] and BPD [19]
are both high. Moreover, there is some evidence [14,20]
that engagement in treatment of patients suffering from
both disorders is poor.
It has been shown that nearly 30% of ED patients meet
criteria for any personality disorder, while 6.2% have
BPD [21]. In the present study, patients with ED compli-
cated by some of the most damaging BPD symptoms,
namely suicidal behaviour, deliberate self harm andimpulsive behaviours (although not always fulfilling all
BPD criteria) will be included. A review of recent pa-
tients treated at the Eating Disorders Unit at the main
study site, St Ann’s Hospital, suggested that some 20% of
patients seen fulfilled study criteria. Treatment of eating
disorders has a limited evidence base: Cognitive Behav-
iour Therapy (CBT) for bulimia nervosa and binge eating
disorder is the only treatment for which NICE has cited
class A Randomised Controlled Trial (RCT) evidence [18].
For Borderline Personality Disorder, Mentalization Based
Therapy [22], Dialectical Behaviour Therapy (DBT) [23]
and Cognitive Behaviour Therapy [24] have shown
benefit in RCTs. NICE [25] calls for more Randomised
Trials to evaluate all these and other therapies. For
patients with both ED and BPD, DBT has shown
promise in small pilot studies [26,27]. MBT has a
theoretical basis in attachment theory and deficits in
primary attachments have been shown in both Eating
Disorders [28] and Borderline Personality Disorder
[29]. Skårderud [30,31] has argued for the importance of
impaired mentalization and the relevance of MBT in in
anorexia nervosa. MBT therefore has a theoretical basis
which may have significance for the aetiology as well as
the treatment of ED/BPD. We have therefore used MBT in
the current trial, adapted for participants with Eating
Disorders and the modified therapy is called MBT-ED [32].
Specialist Supportive Clinical Management (SSCM) was
developed as a control therapy in trials of treatment for
anorexia nervosa [33]. We chose it as a control treatment
because it is a manualized treatment that approximates to
treatment as usual for eating disorders. In the current trial
patients can have any eating disorder diagnosis, and so the
Therapy manual for SSCM was adapted for use with any
eating disorder and the modified therapy called SSCM-
ED. Except for the paragraph headed “Control condition”
below, we have used the terms MBT and SSCM in this
paper to indicate the modified therapies used in the study.
The intended participants in this trial suffer from com-
plex problems which can adversely influence clinical care.
We therefore embarked on a randomized controlled trial of
Mentalization Based Therapy against Specialist Supportive
Clinical Management in patients with a diagnosis of an eat-
ing disorder and either BPD or symptoms of BPD and here
present the protocol for that study.
Objectives of the trial
Primary objective
To ascertain whether Mentalization Based Therapy is
clinically effective at reducing observer rated symptoms of
Eating Disorder, using an accepted measure, the Eating
Disorders Examination, in patients with combined eating
and borderline personality disorder symptoms up to
18 months post randomisation compared to Specialist
Supportive Clinical Management.
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1. To ascertain whether Mentalization Based Therapy
is cost effective at reducing observer rated
symptoms of Eating Disorder, using an accepted
measure, the Eating Disorders Examination, in
patients with combined eating and borderline
personality disorder symptoms up to 18 months
post randomisation compared to Specialist
Supportive Clinical Management.
2. To determine whether Mentalization Based Therapy
is clinically effective at reducing symptoms of
Borderline Personality Disorder as measured by the
Zanarini-BPD scale, an accepted measure of BPD
symptoms [34] in patients with combined eating
disorders and borderline personality disorder
symptoms up to 18 months post randomisation
compared to Specialist Supportive Clinical
Management.
3. To ascertain whether adverse events in the two
groups differ.
4. To study possible mediators of change (e.g. reflective
function, mentalizing, object relations, personality)
in order to provide information on how changes
might occur during therapy.
5. To ascertain whether MBT is a cost-effective
treatment for BPD compared to SSCM.Methods
Study design
This is a multi-centre study across five Clinical Centres,
three NHS Eating Disorder Units and two NHS Person-
ality Disorder Units in three different NHS Trusts.
The design is a single-blind (researchers being blind)
randomised controlled trial of Mentalization Based
Therapy for eating disorders (MBT-ED), with an inten-
sity of one individual and one group session per week
for one year, compared to Specialist Supportive Clinical
Management adapted for all eating disorders (SSCM-ED),
a standard treatment for eating disorders, which com-
prises one session every 1 to 4 weeks for 20 to 26 sessions
All trial participants have access to 5 hours of dietetic
advice over the course of treatment.
Participants will be recruited from the participating
clinics and will include both new referrals and patients
currently receiving care. Randomisation will be remote so
ensure researcher blindness to treatment allocation.
Treatment will begin following randomization for
12 months (MBT-ED group) or for up to 12 months
(SSCM-ED group). All participants will be asked to
complete assessment questionnaires and to participate
in assessment interviews at 6, 12 and 18 months
follow-up.Participants
Inclusion criteria
1. Over 18
2. Eating Disorder diagnosis (DSM IV [35])
3. BPD symptoms
4. Able and willing to provide written informed consent
The criteria for “BPD symptoms” are that the patient
fulfils both behavioural criteria of the DSM IV, namely 1.
impulsivity in at least two areas that are potentially self-
damaging (e.g. spending, sexual behaviour, substance
abuse, reckless driving, binge eating). 2. recurrent suicidal
behaviour, or self-mutilating behaviour.
Exclusion criteria
1. Current psychosis based on the MINI examination [36]
2. Current inpatient or day-patient (attending 3 or
more days per week)
3. Currently in individual or group psychological
therapy
4. Received MBT <6 months prior to randomization
5. Organic brain disease leading to significant cognitive
impairment
6. Body Mass Index (BMI) less than 15 kg/m2 (Normal
range 19-25, Anorexia Nervosa <17.5)
Design and procedure
Recruitment and consent
We aim to include all patients with current eating disor-
ders and Borderline Personality Disorder symptoms as
defined above. Participants may be underweight, normal
weight or overweight, although because of the increased
risk of physical decompensation those severely malnour-
ished (with a BMI of under 15) are excluded. We
will therefore be assessing the effectiveness of MBT in
patients with different eating and weight problems. In
addition to their eating disorder, we anticipate that most
participants will have current self harm and impulsive
behaviours and a sub-group will fulfill all criteria for
BPD. In addition, a group of participants will fulfill criteria
for BPD without necessarily experiencing self harm or
impulsivity.
The initial introduction to the study will come from
the treating clinician. If interested in obtaining more
information, the clinician will provide the Participant
Information Sheets and Carer Information Sheets. At
least 24 hours later, the potential participant will be
approached by a member of the research team and if
still interested, an interview time arranged. At that
meeting the study will be described, outstanding ques-
tions answered and the potential participant asked to
sign the consent form which will be countersigned by
the member of the research team.
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interviews:
Eating Disorders Examination (EDE) [37,38]
Reflective Function Questionnaire (RFQ)a
Reading the mind in the eyes test [39].
Object Relations Inventory (ORI) [40].
Acts of Deliberate Self Harm Inventory (ADSHI) [41].
MINI International Neuropsychiatric
Schedule (MINI), [36].
Structured Clinical Interview for DSM-IV
Axis II Personality Disorders (SCID-II), [42].
Global Assessment of Functioning (GAF) [35].
Zanarini-BPD (ZAN-BPD) [34].
Euroqol (EQ5D) [43].
Depression, Anxiety, Stress Scales -21 (DASS 21) [44].
Modified Social Adjustment Scale (SAS) [45].
Adult Service Use Schedule (AD-SUS) [46].
Big Five personality Inventory (BFI) [47].
Apart from the MINI and the SCID II which are only
administered at baseline for diagnostic purposes, all
instruments will be repeated at 6, 12 and 18 months
post randomization.
The original signed consent form will be retained in
the Investigator Site File, with a copy in the participants’
hospital medical notes, and a copy retained by the par-
ticipant for their information. The participant will spe-
cifically consent to their General Practitioner (GP) being
informed of their participation in the study.
The right to refuse to participate without giving reasons
will be respected.
Trial monitoring safety assurance
Three trial monitoring committees will be formed:
1. Trial Management Committee (TSC): This will
manage the day to day running of the trial and
comprise the Chief Investigator, the Trial Manager
and relevant members of the research team, as
appropriate. It will meet weekly.
2. Independent Data Monitoring Committee (iDMC):
This will have an open and a closed session at each
meeting. The chair will be an independent academic
and members will include an independent Eating
Disorders expert and an Independent general
Academic Psychiatry expert. The Chief Investigator
and the Trial Statistician, who will provide reports,
the Trial Manager and the Trial Statistician will be
in attendance. Of the latter, only the Trial
Statistician will attend the closed part of the
meeting. In the closed part, summaries of follow-up
assessments and adverse events, will be available for
each of the treatment groups (labelled a and b).iDMC meetings will be held annually, or more often
if required and the chair will advise the Trial
Steering Committee of their recommendations
regarding continuation, stopping early or
modifications to the protocol.
3. Trial Steering Committee (TSC): The TSC will be
chaired by an independent expert and members will
include experts in Eating Disorders and General
Psychiatry (different from those in the iDMC) as
well as user and carer representatives, a lead trust
representative and the Chief Investigator, who will
provide a report, the Trial Manager and the Trial
Statistician. Meetings will be annual, or more
frequently should the need arise.
Randomisation, allocation concealment and protection
against bias
Due to the nature of the intervention blinding of partici-
pants and therapists will not be possible. However the
Trial Statistician and Research Workers responsible for
the collection of the assessments will remain blind to
treatment allocation during the trial and primary ana-
lyses. Participants will be asked to be careful not to
divulge what sort of therapy they have had, or other
information that could interfere with the Research
Worker’s blindness to treatment group.
Following completion of the baseline questionnaire,
patients who consent to take part in the trial are randomly
allocated to MBT or SSCM (ratio 1:1) by sites via an on-
line system based at the King’s Clinical Trials Unit based
at the Institute of Psychiatry in London. The method of
randomisation of participants will be by block randomisa-
tion stratified by BMI (15.0-18.5, 18.6-24.9, >25) and
service type (eating disorders unit or personality disorders
unit). Randomly varying block sizes will be implemen-
ted in order to maintain pre-randomisation allocation
concealment.
Safety monitoring
Safety will be monitored in several ways.
1. Physical safety: Clinical features that influence safety
such as weight, muscle strength, serum potassium
and electrocardiograph will be identified at initial
assessment. Monitoring will be done at intervals
recommended by the Centre Clinical Lead. If
changes occur, they will be discussed in supervision
and if appropriate, with a Clinical Centre doctor.
Monitoring will be done at the Clinical Centre, or by
the GP. If the latter, agreement in advance will be
obtained from the GP to do the monitoring tests.
The therapist will be responsible for making sure
that safety monitoring is carried out and results
obtained and interpreted by an appropriate
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will be communicated to the GP.
2. Self harm and suicide: If a participant discloses
thoughts of self harm or suicide during a therapy
session, these will be explored in the session.
Following the session the findings will be discussed
with a supervisor, a doctor, or senior clinical staff at
the Clinical Centre and appropriate action decided
upon. This could include a session shortly after the
current session, either with the therapist or another
staff member, a referral for urgent psychiatric
assessment or a referral for crisis management.
3. Safety outside clinic hours: Clinic Centre staff will
be available during office hours, 9am to 5pm,
Monday to Friday. Outside these hours participants
who are concerned about their safety for any reason
will be asked to contact their GPs or, if urgent, to
attend Accident and Emergency, calling an
ambulance if necessary.
4. Management of crises: Urges to self harm, actual self
harm or suicidal intent: During office hours patients
will call their therapy centre and speak to a staff
member. If necessary the patient will be seen as
soon as possible by a staff member. When the
patient is seen, support will be given, necessary
medical treatment arranged in consultation with a
physician and a risk assessment made to inform a
decision on referral on to local crisis services for
possible admission either to a psychiatric ward or a
crisis facility if available. If admitted, the Therapist
will maintain contact and the patient returned to the
outpatient care of the therapy team as soon as
possible as long as the level of risk is thought to be
acceptable by the treating team consultant
psychiatrist, the Centre Clinical Lead and the
Therapist.
5. Physical symptoms: Weight loss, increasing
abnormality of physical tests or any other worrying
symptoms, will be discussed with the team physician
and a management decision made. This might
include increased frequency of monitoring, a
physician review and consideration of increased
dietetic advice, day hospital attendance or inpatient
admission. The latter could be to a general hospital
nutrition unit, a general adult psychiatry bed or an
eating disorders bed.
Interventions
All participants will have an allocated psychiatrist, a key
worker/therapist who will also provide individual ther-
apy and a dietician who will provide up to 5 hours of
advice over the duration of the trial the timing of which
will be agreed between the participant and the therapist.
From recruitment, Participants will receive treatmentfor 12 months (MBT group) or up to 12 months
(SSCM group).
Experimental condition: mentalization based therapy
This treatment is based on the Intensive Outpatient
Therapy model [29]. The Therapist will provide a weekly
50 minute individual MBT session. During therapy the
Therapist will be responsible for making sure that phys-
ical measures are monitored (e.g. at the clinic, or by the
GP), consulting with the clinic physician as required. Par-
ticipants will also attend weekly group Mentalization
Based Therapy for 90 minutes. Therapy will last for
12 months after which patients will be reassessed by a
member of the trial clinical team and referred for further
management if required. Each MBT group will have a
maximum of 10 participants. Participants will be consid-
ered compliant of they attend at least 50% of individual
and 50% of group sessions offered.
Other treatments: Families and carers will be offered
attendance at existing support services as will control
families, and attendance will be monitored. Should pa-
tients access treatment outside the trial, this will be
monitored and specified at the 6 monthly interviews.
Control condition - specialist supportive clinical
management
SSCM was developed by McIntosh et al [33] as a standard
treatment for anorexia nervosa (AN) and has been used in
several AN trials. [48-50]. It has been modified in collab-
oration with Dr McIntosh to cover eating disorders in
which underweight is not a feature. This extended form
has been called SSCM-ED. SSCM has been found to be an
effective intervention for anorexia nervosa. It is symptom
focused and lacks attention to mentalization or relation-
ships. Hence, it represents a comparison treatment that
offers the control participants a proven treatment, which
does not aim to alter the specific target symptoms which
are addressed in MBT. SSCM offers 20 sessions that can
vary in both length (30-60 minutes) and frequency (2 per
week, to 1 per two weeks depending upon clinical need).
At the end of the 20 sessions, therapists can offer a few
more sessions if required (up to 6) before ending. Partic-
ipants will be considered compliant if they attend at least
50% of sessions offered.
Therapy training, supervision and adherence
Mentalization based therapy
Staff providing individual therapy will have a basic clin-
ical training (e.g., Mental health nursing, psychology or
social work, art therapy, medicine), will have undergone
an introduction to MBT and and treated at least one pa-
tient using MBT under appropriate supervision for 6
months. Those providing group therapy will in addition
have acted as a co-therapist for 6 months in a supervised
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enced MBT practitioner. Therapists in the MBT arm will
not be required to have had specialist training or experi-
ence in Eating Disorders.
Supervision sessions will be conducted by trained super-
visors, expert in provision and supervision of MBT and
with specialist knowledge of Eating Disorders and occur
weekly for one hour. Issues arising in both individual and
group therapy will be discussed. A proportion of individual
sessions will be audio-recorded and the recordings played
and discussed in supervision. Participants will sign consent
forms for audio recordings.
MBT sessions will be audio recorded and the recordings
rated by trained observers to assess the degree to which
therapy provided adheres to the treatment model of MBT.
The rating scale used will be Bateman and Fonagy [29]. In
addition, reports from supervisors on each therapist will
assess adherence to model. Therapists found not to reach
an accepted level of adherence will be provided with add-
itional training. Group therapy model adherence will be
monitored using audio-recordings of therapy sessions and
reports from co-therapists.
Patients (accompanied by a relative if the patient wishes)
will be offered regular treatment review meetings includ-
ing medication review, during outpatient sessions in the
referring team.
Specialist Supportive Clinical Management
As is the case for MBT therapists those providing SSCM will
have a basic Mental Health Professional training. They will
also have had at least 6 months supervised practice with pa-
tients with Eating Disorders. In addition, they will be trained
in the use of the SSCM-ED manual by a senior clinician over
the course of a one-day training. Supervision and discussion
of treatment intensity and duration and clinical review will
be by a senior clinician in the research team and therapy
adherence will be checked during clinical supervision.
Clinical review will be during outpatient sessions in
the referring team.
Assessments, outcome measures, moderators and
mediators
Participants will be referred by clinical staff who will be
asked to indicate diagnosis and BPD symptoms on a referral
sheet. These will be checked at initial research assessment.
The EDE will be used to check Eating Disorder diagnoses
and the SCID-II [42] and the ZAN-BPD [34] to check
Borderline Personality Disorder symptoms and diagnoses.
Primary outcome measure
The Eating Disorders Examination (EDE) interview [38]
will provide information to establish eating disorder
diagnosis and severity.Secondary outcome measures
The Zanarini-BPD (ZAN_BPD) [34] will measure Borderline
Personality Disorder symptoms.
The Acts of Deliberate Self Harm Inventory [24] will
be used to monitor self harm.
Health Related Quality of Life will be measured using
the EQ5D [43].
Health Economics data (use of health resources) will
be monitored using the AD-SUS [46].
Depression, anxiety and stress will be measured using
the DASS-21 [44].
Measures of possible mediators of change
Possible mediators are depicted in Figure 1.
Reflective function will be measured using the Reflective
Function Questionnaire (RFQ)a.
Mentalization will be assessed using the Reading the
Mind in the Eyes Test [39].
The complexity with which participants describe their
parents, themselves and their therapists will be assessed
using the ORI [40].
Personality will be assessed using the BFI [47].
Adverse events
Adverse incidents will be reported to the TSC and the
iDMC.
Statistical analysis
Power calculation
An overall sample size of 140 (randomised 1:1) would
provide over 90% power to detect an effect size of
d=1.07 on the Global EDE Score using an analysis of
covariance with 2 sided 5% significance tests. This calcu-
lation is based on the conservative assumption of a zero
correlation between baseline and post treatment scores
on the EDE and allows for clustering within therapy
groups and 25% attrition. The effect size (1.07) was
based on a minimal clinically important difference, at 18
months post randomization, of 1.5 on the EDE, with a
pooled standard deviation of 1.4 [38]. The MBT arm
consists of a group treatment so has been inflated to
allow for correlation between the measures of those par-
ticipants in the same group therapy Assuming an aver-
age group size of 10 and an intraclass correlation
between Global EDE scores of 0.07 we considered a
design effect of 1.63.
Analysis
Statistical analysis will be carried out in Stata. Mediation
modeling may require the use of specialist structural
equation modeling software (e.g. Mplus). All treatment
group comparisons will be carried out on an intention-
to-treat basis, that is subjects will be analysed in the
Intervention:
MBT-ED
Intervention:
SSCM-ED
Moderators:
ED diagnosis
PD diagnosis
Age
Sex
Co-
morbidities
Mediators:
Object 
relations 
(ORI)
Mentalizing 
(RFQ), 
Reading the 
mind in the 
eyes
2o outcome 
ZAN-BPD
Self harm
Depression/
anxiety
Social 
adjustment
Costs of 
illness and 
treatment
1o  outcome:
EDE global 
score
Figure 1 Interventions, mediators, moderators and outcomes studied.
Robinson et al. BMC Psychiatry 2014, 14:51 Page 7 of 10
http://www.biomedcentral.com/1471-244X/14/51group to which they were randomised irrespectively of
the treatment received.
The primary and secondary longitudinal outcomes will
be analyzed using linear mixed modelling (LLM) [51]. In
this model the outcome variable measured at the post
treatment time points (here 6, 12 and 18 months) is the
dependent variable with outcome at baseline (EDE),
treatment (MBT or SSCM), time (12 or 18 months), a
treatment × time interaction and stratification factors
(BMI and service type) as covariates. To account for
correlation between repeated measures on the same
individual a subject varying intercept will be included.
To allow for correlation between EDE measures within
the same therapy group, a further random effect will be
included that varies with therapy arm.
Treatment effects on any secondary outcomes will be
assessed in the same way, allowing for any deviations
from a non-normal data by generalisations of the LMM.
Analyses that are based on maximum likelihood and
will provide valid inferences under a missing at random
(MAR) missingness mechanism. Sensitivity analyses will
be used to assess the robustness of conclusions to missing
outcome data and to departures from randomised treat-
ment in the manner of [52].
Analyses of mediation at 18 months will use a regres-
sion approach as described by Holmbeck [53, 54], to-
gether with more recent statistical methods [54] to allow
for possible hidden confounding between the mediator
and outcome.Economic evaluation
The economic evaluation will take a NHS/PSS perspec-
tive as recommended by NICE, including the cost of all
hospital and community health and social care services.
Resource use information will be collected using a modi-
fied version of the Adult Service Use Schedule (AD-SUS).
Resource use data will be combined with appropriate
national unit costs to calculate the total cost of the
intervention and control groups. The cost of the MBT
will be directly calculated from salaries using a micro-
costing approach [55]. Differences in mean total costs
between groups will be compared using the standard t-test
with ordinary least squares regression used for adjusted
analyses and the validity of results confirmed using boot-
strapping [56]. The cost-effectiveness of the intervention
will be assessed through the calculation of incremental
cost effectiveness ratios, using the primary outcome
measure and cost-utility will be assessed through the
calculation of QALYs based on the EQ-5D. Uncertainty
around the cost and effectiveness estimates will be repre-
sented using cost-effectiveness acceptability curves [57].Ethical review and trial registration
The study was reviewed by the South East Research
Ethics Committee (Reference 10/H1102/2) and a favourable
opinion was granted on 15/2/10.
Trial registration: The trial was registered on Current
Controlled Trials ISRCTN51304415.
Robinson et al. BMC Psychiatry 2014, 14:51 Page 8 of 10
http://www.biomedcentral.com/1471-244X/14/51Discussion
This innovative project will evaluate a modification of an
established treatment in a patient population with a
common and serious combination of conditions which
are dangerous, sometimes fatal, and currently treated by
multiple agencies which often fail adequately to meet
their needs. Patients with symptoms of both BPD and
Eating Disorder are treated by separate services ad-
dressing nutrition, drug abuse, self-harm and mood and
impulse control and other problems. In this study,
Mentalization Based Therapy which has been found
effective in patients with BPD alone, will form the core
of the treatment which will be administered by a single
team, with the help of emergency services as needed
and all participants will receive dietetic counselling. If
effective, the treatment would be relevant to the care of
many seriously ill, often young people who utilize sub-
stantial health care resources across several health sectors
and who are currently regarded as untreatable by some
clinical staff. Because of the efficacy of Mentalization
Based Therapy in BPD, services offering MBT have been
developed in many parts of the UK, and the project could
encourage collaboration between such services and eating
disorder units so that individuals with both Eating
Disorder and BPD symptoms can be offered effective
treatment.
Currently a patient with a combination of an eating
disorder such as bulimia nervosa and a BPD may be re-
ferred to an eating disorders unit, a general psychiatric
team for management of self-harm and depression, a
psychotherapy service, a substance misuse service for
help with cocaine or [58] alcohol abuse and may also
present to the GP, or A and E for emergency treatment
of suicidal or self-harming behaviour such as a drug
overdose or self-cutting. There is no established treat-
ment for this group, although both specialized inpatient
care [59] and outpatient psychotherapy have been tried.
If MBT-ED is found to be helpful, it could be provided
wherever staff trained in outpatient delivery of the ap-
proach are available. Training for the treatment of BPD
using Mentalization Based Therapy is already being pro-
vided on a fairly large scale, and the same could be
achieved for the treatment of patients with both Eating
Disorder and BPD using the newly developed MBT-ED.
Existing training for MBT requires a short (3 day) course
which, together with specialist MBT supervision allows
staff to take on patients and to co-facilitate MBT groups
in a clinical setting with usual NHS provision of re-
sources. The patients are already being referred and seen
by Mental Health Staff including nurses, psychologists
and doctors, and these staff could be trained in the new
approach and patients helped to avoid crisis care, includ-
ing inpatient admissions. Existing staff time, which is
currently not used effectively because of poor complianceand crises, would be redirected to a treatment approach
that could lead to long term improvement and a reduced
need for health care, currently provided in diverse and
sometimes poorly co-ordinated services.
The Aetiologies of both Borderline Personality Disorder
and Eating disorders are incompletely understood. It has
been suggested [60] that experiences in infancy interacting
with genetic and developmental processes, can contribute
to deficits in mentalization which are found in these con-
ditions, raising the possibility that there may be a contri-
bution to their aetiology which is located during the first
decade of life. This study, by investigating mentalization
and object relations in participants undergoing different
forms of therapy may provide useful information which
bears on these ideas.
Endnote
aThe Reflective Function Questionnaire. Fonagy, P. 2010.
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